AKA. Yu. Krylova

A. Yu. Krylova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. Yu. Krylova has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inherited chromosomally integrated Human herpesvirus 6 in patients with blood system diseases

    by T. A. Soldatova, D. S. Tikhomirov, A. Yu. Krylova, E. N. Ignatova, О. Н. Мисько, O. G. Starkova, А. В. Рекстынь, T. A. Tupoleva

    Introduction. Human herpesvirus 6 (HHV-6) is an opportunistic agent causing various complications in patients with hematological diseases. The virus has a unique ability to integrate into telomeres of human chromosomes, which makes hereditary transmission of the viral genome possible. This form of the virus is called inherited chromosomally integrated HHV-6 (iciHHV-6). The iciHHV-6 frequency among patients with blood system diseases is unknown and its signifi cance for clinical practice remains insufficiently studied.Aim — to determine the prevalence of ichHHV-6 in patients with hematological diseases.Materials and methods. Clinical and laboratory data in 4,998 adult patients treated at the National Medical Research Center for Hematology (Moscow, Russia) from 2020 to 2024 were analyzed. Clinical materials obtained from patients were examined by molecular-biological methods for the presence of HHV-6 DNA.Results. IciHHV-6 was confirmed in 14 out of 4,998 (0.26 %) enrolled patients. 5 patients (38,5 %) had clinical manifestations of herpesvirus infection during treatment, while the other 9 patients (61.5 %) showed no signs of the infection. 5 of 14 iciHHV-6-positive patients underwent hematopoietic stem cell transplantation. Criteria and laboratory tests for suspicion for iciHHV-6 were designed and successfully verified, which made it possible to suspect and prove the presence of hci-HCV-6.Conclusion. The presence of ichHHV-6 among patients with hematological diseases was detected in 0.26 % of cases. The high concentration of HCV-6 DNA during polymerase chain reaction testing, as well as the absence of negative virological results during antiviral therapy, make it possible to suspect HCV-HCV-6. Screening for iciHHV-6 by qPCR of hair follicles and nails is recommended for patient with high viremia. A positive result in such tests confirms iciHHV-6-positive status. The efficiency of antiviral therapy in iciHHV-6-individuals requires further research. During transplantation of allogeneic hematopoietic stem cells to a recipient-carrier of hci-HCV-6, HCV-6 reactivation, asymptomatic persistence of high viremia, and a dramatic decrease of the viral load are all possible.


  • Open Access

    Formation of collective immunity against a new coronavirus infection COVID-19 in blood donors

    by O. G. Starkova, E. N. Ovchinnikova, D. S. Tikhomirov, О. Н. Мисько, T. A. Soldatova, A. Yu. Krylova, E. N. Ignatova, T. A. Tupoleva, T. V. Gaponova

    Introduction. The new coronavirus infection COVID-19, fi rst detected at the end of 2019 in the Chinese city of Wuhan, caused a worldwide pandemic. High mortality among people with chronic diseases, a high frequency of the severe form of the disease, and an unspecifi ed number of asymptomatic carriers are all causes for heavy burden on the healthcare system, including the blood bank service.Aim – to assess the SARS-CoV-2 antibody formation in blood donors.Materials and methods. The research included test results for 12,314 blood samples of donors who donated blood during 04.29.2020 – 08.04.2021 at the National Medical Research Center for Hematology (Russia). Anti-RBD-SARS IgG were tested by «SARS-CoV-2-IgG-ELISA», manufactured by the National Medical Research Center for Hematology, LLC «HEMA» (Russia).Results. Among 12,314 blood samples from donors, 3,219 (26.14 %) were positive for antibodies to SARS-CoV-2. Antibodies detection rate increased from 8.52 to 58.09 % during the observation period. For representative evaluation of donors’ anti-SARS antibodies growth profi le, the results of detection were analyzed within two-week periods (including holidays). This approach made it possible to avoid counting the same donor twice. In the profi le of the growth of collective immunity in donors, two periods were identifi ed: May – November 2020 and November 2020 – April 2021. The period of May – November 2020 proved no signifi cant change in antibodies detection in donors. Detection rate was stable at about 15 % (13.10–16.24 %). The second period, from November 2020 to April 2021, demonstrated sustainable growth of this parameter from 16.20 to 58.09 %. This is likely due to the start of the second wave of COVID-19 in Russia (starting from November 2020) and an active campaign for mass vaccination that started in December 2020. To assess the true rate of increase of specifi c immunity in donors, the frequency of primary detection of antibodies to SARS-CoV-2 in donors in relation to those donors in whom antibodies were detected earlier was analyzed. The contribution of cases of primary detection of antibodies to SARS-CoV-2 was wave-like and corresponded to the epidemiological situation.Conclusion. An increase in the frequency of detection of antiviral antibodies in gratuitous blood donors was found during the spread of the second wave of COVID-19 and the n the beginning of mass vaccination. The increase in the overall frequency of antibody detection was due to donors with newly and re-detected antibodies. The surge in the frequency of primary detection of antibodies in blood donors corresponded to the second wave of infection.